DIACEUTICS PLC

Report Publication Announcement • Jun 7, 2021

National Storage Mechanism | Additional information

RNS Number : 9510A

Diaceutics PLC

07 June 2021

7 June 2021

Diaceutics PLC 

("Diaceutics" or "the Group")

Notice of Capital Markets Day

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that it will be hosting a virtual Capital Markets Day ("CMD") for investors and equity analysts on Wednesday 16th June 2021, starting at 13:00pm BST.

The event will be hosted by Group CEO, Peter Keeling, and will include a series of presentations, a demonstration of the DXRX SaaS platform, views from an industry expert panel including:

·    Pharmaceutical Partner: a senior executive within one of the world's top five pharmaceutical companies

·    Laboratory Partner: Professor Giancarlo Pruneri, Head of Pathology Fondazione IRCCS Istituto Nazionale Tumori, Milan

·    Key Opinion Leader: Dr Avi Kulkarni, SVP and R&D leader at Nasdaq listed technology firm Cognizant

In addition, there will be a strategic update from the Company, along with a live Q&A.

A video replay of the presentation will be available via the Group's website post-event.

If you are interested in attending or have any questions relating to the Diaceutics Capital Markets Day please contact diaceutics@almapr.co.uk 

Enquiries:

Diaceutics PLC Peter Keeling, Chief Executive Officer Philip White, Chief Financial Officer	www.diaceutics.com via Alma PR
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison  Stewart Wallace Nick Adams	+44 (0)20 7710 7600
Alma PR Caroline Forde Robyn Fisher Kieran Breheny	Tel: +44 (0)20 3405 0205 diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFFFSIREIEIIL